Real-world vision in age-related macular degeneration patients treated with single antiâVEGF drug type for 1 year in the IRIS Registry
Ophthalmology Nov 17, 2017
Rao P, et al. - The intent of the researchers was to compare real-world visual acuity (VA) in patients with neovascular age-related macular degeneration (nAMD) treated with a single antiÂvascular endothelial growth factor (VEGF) drug monotherapy for 1 year. It was deduced that treatment with bevacizumab, ranibizumab, and aflibercept drugs led to a similar improvement in the VA, over 1 year of monotherapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
